121 related articles for article (PubMed ID: 38447438)
1. A novel turn-on fluorescence sensor based on the Nd (III) complex for the ultrasensitive detection of 6-mercaptopurine.
Rajpal ; Jana S; Ojha RP; Prakash R
Spectrochim Acta A Mol Biomol Spectrosc; 2024 May; 313():124056. PubMed ID: 38447438
[TBL] [Abstract][Full Text] [Related]
2. Determination of 6-mercaptopurine based on the fluorescence enhancement of Au nanoparticles.
Shen XC; Jiang LF; Liang H; Lu X; Zhang LJ; Liu XY
Talanta; 2006 Apr; 69(2):456-62. PubMed ID: 18970589
[TBL] [Abstract][Full Text] [Related]
3. Magnetic nanoparticles based on cerium MOF supported on the MWCNT as a fluorescence quenching sensor for determination of 6-mercaptopurine.
Ashrafzadeh Afshar E; Taher MA; Karimi-Maleh H; Karaman C; Joo SW; Vasseghian Y
Environ Pollut; 2022 Jul; 305():119230. PubMed ID: 35395348
[TBL] [Abstract][Full Text] [Related]
4. Zinc-doped hydroxyapatite as a pH responsive drug delivery system for anticancer drug 6-mercaptopurine.
Jakubowski M; Majchrzycki Ł; Zarkov A; Voelkel A; Sandomierski M
J Biomed Mater Res B Appl Biomater; 2024 Mar; 112(3):e35395. PubMed ID: 38433609
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of tablet and liquid formulations of oral 6-mercaptopurine in children with acute lymphoblastic leukemia.
Larsen RH; Hjalgrim LL; Grell K; Kristensen K; Pedersen LG; Brünner ED; Als-Nielsen B; Schmiegelow K; Nersting J
Cancer Chemother Pharmacol; 2020 Jul; 86(1):25-32. PubMed ID: 32519032
[TBL] [Abstract][Full Text] [Related]
6. 6-mercaptopurine: high-dose 24-h infusions in goats.
Schouten TJ; De Abreu RA; Schretlen ED; van Baal JM; van Leeuwen MB; de Vaan GA
J Cancer Res Clin Oncol; 1986; 112(1):61-6. PubMed ID: 3733868
[TBL] [Abstract][Full Text] [Related]
7. Metabolism of intravenously administered high-dose 6-mercaptopurine with and without allopurinol treatment in patients with non-Hodgkin lymphoma.
Keuzenkamp-Jansen CW; DeAbreu RA; Bökkerink JP; Lambooy MA; Trijbels JM
J Pediatr Hematol Oncol; 1996 May; 18(2):145-50. PubMed ID: 8846126
[TBL] [Abstract][Full Text] [Related]
8. Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine.
Korelitz BI; Mirsky FJ; Fleisher MR; Warman JI; Wisch N; Gleim GW
Am J Gastroenterol; 1999 Nov; 94(11):3248-53. PubMed ID: 10566724
[TBL] [Abstract][Full Text] [Related]
9. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia.
Relling MV; Hancock ML; Boyett JM; Pui CH; Evans WE
Blood; 1999 May; 93(9):2817-23. PubMed ID: 10216075
[TBL] [Abstract][Full Text] [Related]
10. Adsorption of 6-mercaptopurine and 6-mercaptopurine-ribosideon silver colloid: a pH-dependent surface-enhanced Raman spectroscopy and density functional theory study. II. 6-mercaptopurine-riboside.
Szeghalmi AV; Leopold L; Pînzaru S; Chis V; Silaghi-Dumitrescu I; Schmitt M; Popp J; Kiefer W
Biopolymers; 2005 Aug; 78(6):298-310. PubMed ID: 15832317
[TBL] [Abstract][Full Text] [Related]
11. 6-Mercaptopurine: total body autoradiograms and plasma concentration-time curves of 6MP and metabolites from marmoset monkeys.
Schouten TJ; De Abreu RA; Schretlen ED; de Vaan GA; van der Kleijn E
Pediatr Hematol Oncol; 1986; 3(2):159-65. PubMed ID: 3153226
[TBL] [Abstract][Full Text] [Related]
12. 6-Mercaptopurine: cytotoxicity and biochemical pharmacology in human malignant T-lymphoblasts.
Bökkerink JP; Stet EH; De Abreu RA; Damen FJ; Hulscher TW; Bakker MA; van Baal JA
Biochem Pharmacol; 1993 Apr; 45(7):1455-63. PubMed ID: 7682415
[TBL] [Abstract][Full Text] [Related]
13. Assessment of mercaptopurine (6MP) metabolites and 6MP metabolic key-enzymes in childhood acute lymphoblastic leukemia.
Wojtuszkiewicz A; Barcelos A; Dubbelman B; De Abreu R; Brouwer C; Bökkerink JP; de Haas V; de Groot-Kruseman H; Jansen G; Kaspers GL; Cloos J; Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2014; 33(4-6):422-33. PubMed ID: 24940700
[TBL] [Abstract][Full Text] [Related]
14. A MnO
An X; Chen R; Chen Q; Tan Q; Pan S; Liu H; Hu X
Mikrochim Acta; 2021 Apr; 188(5):156. PubMed ID: 33825037
[TBL] [Abstract][Full Text] [Related]
15. Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activity.
Levinsen M; Rosthøj S; Nygaard U; Heldrup J; Harila-Saari A; Jonsson OG; Bechensteen AG; Abrahamsson J; Lausen B; Frandsen TL; Weinshilboum RM; Schmiegelow K
Cancer Chemother Pharmacol; 2015 Jan; 75(1):59-66. PubMed ID: 25347948
[TBL] [Abstract][Full Text] [Related]
16. 6-mercaptopurine dosage and pharmacokinetics influence the degree of bone marrow toxicity following high-dose methotrexate in children with acute lymphoblastic leukemia.
Schmiegelow K; Bretton-Meyer U
Leukemia; 2001 Jan; 15(1):74-9. PubMed ID: 11243403
[TBL] [Abstract][Full Text] [Related]
17. Gold nanoparticles loaded chitosan encapsulate 6-mercaptopurine as a novel nanocomposite for chemo-photothermal therapy on breast cancer.
Faid AH; Shouman SA; Badr YA; Sharaky M; Mostafa EM; Sliem MA
BMC Chem; 2022 Nov; 16(1):94. PubMed ID: 36371236
[TBL] [Abstract][Full Text] [Related]
18. The use of xanthine oxidase for a specific and sensitive fluorimetric determination of 6-mercaptopurine in serum.
Tawa R; Takeshima S; Hirose S
Biochem Med; 1984 Dec; 32(3):303-10. PubMed ID: 6549126
[TBL] [Abstract][Full Text] [Related]
19. In vitro metabolism of 6-mercaptopurine by human liver cytosol.
Rowland K; Lennard L; Lilleyman JS
Xenobiotica; 1999 Jun; 29(6):615-28. PubMed ID: 10426560
[TBL] [Abstract][Full Text] [Related]
20. Oral administration of non-absorbable delayed release 6-mercaptopurine is locally active in the gut, exerts a systemic immune effect and alleviates Crohn's disease with low rate of side effects: results of double blind Phase II clinical trial.
Israeli E; Goldin E; Fishman S; Konikoff F; Lavy A; Chowers Y; Melzer E; Lahat A; Mahamid M; Shirin H; Nussinson E; Segol O; Ya'acov AB; Shabbat Y; Ilan Y
Clin Exp Immunol; 2015 Aug; 181(2):362-72. PubMed ID: 25846055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
